"Cyclohexanes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Six-carbon alicyclic hydrocarbons.
Descriptor ID |
D003510
|
MeSH Number(s) |
D02.455.426.392.368.367
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclohexanes".
Below are MeSH descriptors whose meaning is more specific than "Cyclohexanes".
This graph shows the total number of publications written about "Cyclohexanes" by people in this website by year, and whether "Cyclohexanes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 |
2007 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclohexanes" by people in Profiles.
-
Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. AIDS. 2016 Feb 20; 30(4):591-600.
-
Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Huestis MA. Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. Bioanalysis. 2014 May; 6(9):1187-200.
-
Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, Pestell RG. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012 Aug 1; 72(15):3839-50.
-
Chang J, Lenhoff AM, Sandler SI. Solvation free energy of amino acids and side-chain analogues. J Phys Chem B. 2007 Mar 1; 111(8):2098-106.
-
Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol. 2004 Oct; 54(4):308-14.